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In polarized epithelium direction of viral entry and release correlates with proclivity of a virus to establish local versus
systemic infection. The Epstein–Barr virus (EBV), whose principal tissue reservoir is B lymphocytes, also has disease
manifestations in epithelium, suggesting intertissue spread potentially influenced by epithelial cell polarity. We stably
transfected the B lymphocyte EBV receptor (CR2/CD21) into Madin–Darby canine kidney (MDCK) epithelial cells used
extensively to study effects of cell polarity on infection by both DNA and RNA viruses. CR2/CD21 was detected on both apical
and basolateral surfaces of polarized MDCK cells, with predominant expression basolaterally. However, infectivity was up to
four-fold greater apically, suggesting that endogenous cell surface molecules, sorted asymmetrically onto polarized plasma
membranes, may be involved in EBV entry into MDCK cells. EBV gp350/220, a replicative cycle glycoprotein added to the
virus envelope on egress through the cell membrane, was immunolocalized by confocal microscopy to basolateral cell
surfaces only. Apical entry of EBV with subsequent basolateral release of newly replicated virus favors systemic infection by
viral dissemination to underlying lymphocytic aggregations. Under conditions of long-term culture, latent EBV was not stably
maintained in these cells, suggesting that the epithelial phase of acute EBV infection may be transient. © 2000 Academic PressINTRODUCTION
The late disease manifestations of Epstein–Barr virus
(EBV) infection define predominant tissue tropisms of the
virus: Burkitt’s lymphoma involves B lymphocytes and
nasopharyngeal carcinoma is a malignancy of epithelial
cell derivation. Mucosal epithelium, the first barrier to
viral invasion, must be traversed prior to viral dissemi-
nation and intuitively is thought to participate in the initial
steps of primary EBV infection. Early events are poorly
understood, however, due in part to the inability to pro-
cure timely clinical material. Documentation of the initial
exposure to virus is difficult since EBV is most frequently
transmitted by healthy oropharyngeal shedders of virus.
Moreover, acquisition of the virus is generally asymptom-
atic. Even when primary infection is manifested clinically
as infectious mononucleosis, symptoms become appar-
ent only after a 30- to 50-day incubation period, by which
time viral dissemination has already taken place
throughout the lymphoreticular system (Svedmyr et al.,
1984; Diehl et al., 1968). Thus, studies of acute EBV
disease do not provide a full recapitulation of virus–
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38epithelial cell interactions that occur during primary in-
fection and highlight the need for epithelial cell models
to elucidate EBV pathobiology.
A cardinal property of epithelium unexplored in previ-
ous studies of EBV infection (Li et al., 1992, Knox et al.,
1996; Imai et al., 1998, Fingeroth et al., 1999) is its intrin-
sic polarity. Asymmetric distribution of proteins and lipids
in the plasma membrane, together with the presence of
junctional complexes between adjacent cells, creates
distinct surface domains, one facing the external envi-
ronment and the other contacting underlying cells and
tissue. Viruses may be restricted in entry to one domain
or the other (reviewed in Blau and Compans, 1996),
limiting the sites susceptible to infection. Moreover, the
direction of their release can have important implications
in pathogenesis (Tashiro et al., 1990a,b), with basolateral
budding providing greater opportunity for systemic
spread and interaction with the immune system.
The initial interaction of EBV with B lymphocytes is
through contact of the viral attachment protein, gp350/
220, with cellular CR2 (the type 2 complement receptor;
also designated CD21) (Fingeroth et al., 1984). A complex
of three viral glycoproteins, gH, gL, and gp 42, facilitates
penetration by binding a coreceptor, HLA class II (Li et
al., 1997). Less is known about entry into epithelium
where infection may occur by as yet unidentified recep-
tors (Yoshiyama et al., 1997; Wang et al., 1998; Imai et al.,
1998). However, low levels of CR2 expression sufficient
for EBV infection (Fingeroth et al., 1999) have been de-
tected in human epithelial tumor lines (Birkenbach et al.,
0042-6822/00 $35.00
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388 CHODOSH ET AL.1992; Billaud et al., 1987) as well as in tongue epithelium
Thomas et al., 1991; Webster-Cyriaque and Raab-Traub,
998). Moreover, transfection of the CR2 molecule into
umerous cell types confers susceptibility to infection
Ahearn et al., 1988; Li et al., 1992; Knox et al., 1996). In
arlier work using the Madin–Darby canine kidney
MDCK) epithelial cell line, we demonstrated that epithe-
ial cell polarity was a key determinant in the infectious
utcome of immunoglobulin A-mediated entry of EBV
Gan et al., 1997). In this report, using MDCK cells stably
ransfected with the EBV receptor CR2, we provide evi-
ence for preferential direction of viral entry and release
n polarized cells that may elucidate EBV exchange be-
ween epithelial cells and lymphocytes at the time of
rimary infection.
RESULTS
xpression of CR2 in transfected MDCK cells
cDNA encoding the CR2 open reading frame was
nserted into a mammalian expression vector, pREP4,
hat enables the stable transfection of MDCK cells when
rown under antibiotic selection. To assess levels of CR2
xpression in selected MDCK–pR4CR2 clones, we com-
ared cells containing no vector, the vector alone, or
ector plus insert to the control human lymphoid cell
ines, Reh and IB4 (Fig. 1). The anti-CR2 monoclonal
ntibody (MAb) HB-5 (Tedder et al., 1984) immunopre-
ipitated the CR2 protein (Mr 145,000) from [
35S]methi-
FIG. 1. Expression of CR2 in cloned MDCK transfectant. The 145-kDa
CR2 protein, expressed in lymphoblastoid cell control (IB4) and trans-
fected MDCK clone (MDCK–pR4CR2), was immunoprecipitated from
[35S]methionine-labeled cells with HB-5 MAb as described under Ma-
erials and Methods. Negative controls included the pre-B-lymphocyte
ell line Reh, stock MDCK cells, and cells transfected with vector alone
MDCK–pR4).onine-labeled MDCK–pR4CR2 cells and the lymphoblas-
toid cell line IB-4, but not from MDCK cells alone, MDCK–pR4, or the pre-B cell line Reh that is CR2-negative by
virtue of its pre-B stage of differentiation (Tedder et al.,
1984).
Because EBV entry in polarized epithelium may be
affected by asymmetric sorting of receptor molecules to
a single cell face, we examined CR2 expression on both
the apical and the basolateral cell surface domains.
Duplicate MDCK–pR4CR2 monolayers grown on glass
coverslips were incubated with excess MAb HB5 to
saturate receptor sites apically. Bound antibody was
then labeled by indirect immunofluorescence staining
with Texas red-conjugated reagent. Stained coverslips
were treated with either ethylene glycol-bis(b-aminoethyl
ether)-N,N,N9,N9-tetraacetic acid (EGTA), a chelating
agent that disrupts cellular tight junctions, or control
buffer. Both cell preparations were reincubated with
HB-5 so that CR2 on newly exposed basolateral domains
could be visualized with FITC-conjugated secondary an-
tibody. By dual-color immunofluorescence (Fig. 2), CR2
was evident on both domains in EGTA-treated cells. In
mock-treated cultures where tight junctions between
cells excluded antibody from basal cell surfaces, apical
staining alone was detected. Bipolar expression was
confirmed using confluent cell monolayers grown on
porous (0.45 mm) membrane supports that provided sep-
arate access to basolateral or apical cell surfaces by
immunologic reagents (result not shown).
In polarized MDCK cells, the ratio of apical to basolat-
eral surface area has been reported to vary from 1:1 to
1:4 on MDCK (strain II) cells (von Bonsdorff et al., 1985;
van Genderen et al., 1991), depending on culture condi-
tions. Disproportionate surface areas between apical
and basolateral domains might favor basolateral viral
entry, if receptor molecules were otherwise equally dis-
tributed. To quantify the amount of CR2 expressed api-
cally as opposed to basolaterally, 125I-labeled protein
A-binding assays were performed on filter-grown mono-
layers of MDCK–pR4CR2 cells exposed to anti-CR2 MAb
HB-5. Results from three separate experiments showed
that over 90% of bound antibody was located at the
basolateral surface, with the medium counts per minute
(cpm) on apical versus basolateral membranes being
126 (range 107–180) and 1350 (range 949–2218), respec-
tively. Even considering disparities in surface area, these
results suggest a higher density of CR2 basolaterally that
might enhance a basolateral route of entry by EBV.
Efficiency of infection at apical versus
basolateral surfaces
To assess polarity of EBV entry, MDCK–pR4CR2 cells
were grown on permeable filters and virus was applied
to either the apical or the basolateral cell face. Because
the basolateral cell surface may be partially occluded by
the porous membrane, accessibility to each surface do-
main was first documented by viral adsorption studies
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389EBV INFECTION OF POLARIZED EPITHELIUMusing an excess of radiolabeled Akata virus. When 3H-
labeled EBV was incubated with the CR2-positive lym-
phocyte control, Raji, only 27% of the available counts
were adsorbed, indicating saturation of natural receptor
sites with the virus preparation used (Table 1). Nonspe-
cific adsorption to receptor-negative Reh lymphocytes
was negligible and similar to that occurring with MDCK
cells transfected with vector alone. Moreover, compari-
son of apical versus basolateral counts on the control,
CR2-negative MDCK–pR4 cells indicated that there was
no undue retention of radiolabeled virus within filter
pores (Table 1). When labeled virus was applied to each
side of filter-grown MDCK–pR4CR2 cells, there was
equivalent binding of EBV to both the apical and the
basolateral cell surfaces (Table 1). Interpreted in light of
the marked disparity of CR2 distribution between apical
and basolateral surfaces, equivalent binding is consis-
tent with partial physical obstruction posed by the culture
support membranes as reported previously (Sears et al.,
1991; Tugizov et al., 1996). Nonetheless, for the purpose
of quantifying infectivity, these results indicated that
comparable amounts of labeled virus were bound to
opposing cell surface domains.
Infectivity via each cell face was monitored using in-
direct immunofluorescence and protein immunoblotting
assays for the immediate-early lytic cycle protein, BZLF1
(BamHI Z leftward open reading frame 1). The highly
visible nuclear staining obtained with anti-BZLF1 MAb
BZ.1 provides a readily quantified marker of infection. In
three separate experiments, immunofluorescence stain-
ing for BZLF1 24 h postinfection showed significantly
more EBV-positive cells in monolayers infected apically
than basolaterally (Table 2, Figs. 3A–3C). These findings
were corroborated by immunoblot. The 34- to 38-kDa
BZLF1 protein was detected in cell monolayers infected
apically, whereas only a weak signal was observed in
cells infected basolaterally (Fig. 3D). Thus, despite equal
viral binding at both cell surfaces (Table 1), efficiency of
entry as judged by viral antigen expression was greater
apically.
One explanation for enhanced infectivity observed api-
cally in MDCK–pR4CR2 cells, despite basolateral pre-
dominance of CR2 expression, is the existence of an
endogenous coreceptor restricted to the apical mem-
brane. Of note, control cells without transfected CR2
showed barely detectable levels of infection in repeated
experiments by immunoblotting (Fig. 3D, MDCK–pR4,
lane A) and immunofluorescence staining (not shown).
CR2 could not be immunoprecipitated from these canine-
derived cells with the MAb HB-5 (Fig. 1). PCR primers
specific to human CR2 sequences did not yield a product
from MDCK–pR4 cellular DNA (data not shown). How-
ever, low-efficiency CR2-independent EBV infection of
established human epithelial cell lines, previously
deemed resistant, has been convincingly demonstrated
by infecting with a viral genome carrying a selective
l
imarker (Yoshiyama et al., 1997; Imai et al., 1998). Using
ecombinant EBV in which a neomyocin-resistance cas-
ette was inserted into the BDLF3 open reading frame
Borza and Hutt-Fletcher, 1998), we derived a uniformly
nfected MDCK–pR4 cell population from apically ex-
osed cells selected in medium containing G418 (data
ot shown). Together, these results are consistent with
he notion of a naturally expressed coreceptor distrib-
ted apically that functions synergistically with trans-
ected CR2.
ocalization of gp350 to basolateral cell membranes
Viral envelope glycoproteins accumulate selectively at
he membrane domain from which virus release occurs
Rodriguez-Boulan and Pendergast, 1980; Roth et al.,
983; Owens et al., 1991) and provide a useful correlate
or the site of viral egress in polarized cells. EBV, like
ther herpesviruses, acquires an envelope when pass-
ng through the inner nuclear membrane (Torrisi et al.,
989), but subsequently undergoes what appears to be a
rocess of deenvelopment in the cytoplasm and reenvel-
pment at the plasma membrane (Gong and Kieff, 1990).
lthough little of the EBV glycoprotein gp350/220 is
ound in the nuclear membrane, its density in the plasma
embrane of productively infected lymphocytes is simi-
ar to that in enveloped virus itself.
Infected MDCK–pR4CR2 monolayers, when stained
imultaneously for BZLF1 and gp350/220, revealed nu-
erous BZLF1-positive cells but with only rare concur-
ent expression of the late lytic protein gp350/220 (Fig. 4).
he extent to which the transcriptional transactivator
ZLF1 drives downstream steps of viral replication is
nown to vary in lymphocyte culture (Gradoville et al.,
990), and the discordance seen here between expres-
ion of the immediate-early and late replicative proteins
s consistent with a largely abortive replicative cycle in
his cell system. Indeed, infectious virus was not recov-
red from culture medium at either cell surface.
However, in a series of optical sections taken horizon-
ally through infected MDCK–pR4CR2 cells by confocal
icroscopy, we showed circumferential cell staining us-
ng anti-gp350-220 MAb 2L10 that appeared only at in-
reasing depths (Figs. 5A–5C). Cell sections through the
ertical axis showed a U-shaped distribution of immuno-
luorescence delineating the basal cell surface (Fig. 5D).
oth patterns indicated polar accumulation of gp350/220
n basolateral plasma membranes, consistent with baso-
ateral viral egress.
utcome of infection upon long-term culture
To monitor the state of EBV activation in this cell
ystem over time, we analyzed the configuration of EBV
ermini (Raab-Traub and Flynn, 1986) as a marker of
atent versus replicative infection (Fig. 6). Essentially all
nput viral DNA had circularized into the episomal (latent)
390 CHODOSH ET AL.FIG. 2. Bipolar expression of CR2 in confluent MDCK–pR4CR2 cells. Polarized cell monolayers incubated with anti-CR2 MAb were stained with
Texas red-conjugated anti-mouse immunoglobulin G to denote CR2 on apical membranes. Cell junctions were left intact (A) or disrupted (B) to provide
access to the basolateral surface as described under Materials and Methods, and then monolayers (A and B) were reincubated with anti-CR2 MAb.
Newly bound MAb was detected with fluorescein isothiocyanate-conjugated anti-mouse IgG.
FIG. 3. EBV infectivity at opposing surfaces of polarized MDCK–pR4CR2 cells. MDCK–pR4CR2 cells grown on permeable membrane supports were
exposed basolaterally (A) or apically (B) to the Akata strain of EBV, trypsinized 24 h postinfection, and cytocentrifuged onto slides prior to
immunofluorescence staining for the EBV immediate-early lytic protein, BZLF1. An apically infected MDCK–pR4 control, transfected with vector alone,
is shown in (C). Microscopic fields A–C were randomly selected and are representative of results from three separate experiments. Immunoblotting
for the 34- to 38-kDa BZLF1 protein (D) was performed as described under Materials and Methods on similarly exposed (lane A, apical; lane B,
basolateral) MDCK lines. B95-8 (productively infected) and BL2 (EBV-negative) are lymphoid cell controls.
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391EBV INFECTION OF POLARIZED EPITHELIUMconfiguration by 48 h, with one episomal band predom-
inating by 96 h. A gradual diminution in the intensity of
the hybridization signal for the EBV episomal band oc-
curred over 4 weeks in culture (Fig. 6A). To distinguish
between episomal loss and mere overgrowth by the
noninfected cell population in a mixed culture, single-cell
clones were established in which all cells were shown to
contain the small nonpolyadenylated virus-encoded
RNAs (EBERs), indicating infection with virus (Figs. 6B
and 6C). By RT-PCR and protein analyses (data not
TABLE 1
3H-Labeled EBV Binding to Polarized Cell Surfaces of MDCK Cells
Cells Surface exposed
Median cpm
(range)a
% TCA
countsb
MDCK–pR4CR2 Apical
Basolateral
1005 (589–1556)a
1316 (920–2580)a
14%
18%
MDCK–pR4 Apical
Basolateral
216 (153–3520)a
396 (215–560)d
3%
5%
Rajic (CR2-positive) NAd 1944 27%
ehc (CR2-negative) NA 165 2%
a Median and range counts per minute (cpm) represent four separate
xperiments.
b Total cpm for stock 3H-labeled EBV was 23,135; incorporated cpm
etermined by trichloracetic acid (TCA) precipitation was 7173. % TCA
ounts 5 median cpm/7173.
FIG. 4. Concomitant expression of immediate-early and late lytic
MDCK–pR4CR2 cells. Dual immunofluorescence staining for immedi
red-conjugated goat anti-mouse IgG) and late envelope glycoprotei
antibody) at 72–96 h postinfection.c Lymphocyte control.
d Not applicable.shown), cloned cells exhibited a type II pattern of latent
EBV gene transcription (EBNA1, LMP1, LMP2). Infected
cell clones had a population doubling time of 19 h com-
pared to 24 h for the noninfected MDCK–PR4CR2 cell
clones when seeded at 8 3 103 cells/ml. EBNA1 tran-
scripts could be detected to cell passage 9 in cells
diluted 1:10 at each passage. By passage 14, there was
no longer PCR evidence for either EBNA1 (responsible
for maintenance of the episome) or EBV DNA in infected
MDCK–pR4CR2 cells, indicating instability of viral epi-
some maintenance in this epithelial cell system.
DISCUSSION
The bulk of in vitro studies to date that address epi-
thelial cell infection by EBV have focused on patterns of
viral gene expression and altered cell growth as a model
TABLE 2
BZLF1 Expression after Apical and Basolateral Exposure
of Polarized MDCK–pR4CR2 Cells
Experiment 1 Experiment 2 Experiment 3
pical infectiona 60/255 13/50 37/307
asolateral infectiona 5/63 10/91 9/267
valueb 0.0049 0.0309 #0.0001
BV proteins as a measure of progression in the EBV lytic cycle in
ly protein BZLF1 (localized to the nucleus and detected with Texas
0/220 (detected with fluorescein isothiocyanate-conjugated secondcycle E
ate-eara Expressed as number of positive cells over total cells counted.
b Fisher’s exact two-tailed test.
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392 CHODOSH ET AL.for EBV oncogenicity in nasopharyngeal carcinoma. Re-
sults from our work evaluating infection of polarized
epithelium allow predictions regarding the largely un-
FIG. 5. Immunolocalization of the major EBV envelope glycoprotein
gp350/220 within plasma membranes of polarized MDCK–pR4CR2
cells postinfection. Optical sections on both horizontal (A–C) and ver-
tical (D) axes were taken by confocal microscopy after immunofluores-
cence staining using anti-gp350-220 MAb 2L10 as described under
Materials and Methods. Each photomicrograph represents a compos-
ite of three adjacent 0.7-mm sections at the approximate depth indi-
cated.
FIG. 6. Configuration and long-term maintenance of the EBV genome
s probe for the arrangement of viral termini (joined, high-molecu
ow-molecular-weight ladder array found with the replicating, infectious
lot hybridization as per Raab-Traub and Flynn (1986), shown in (A). Nam
f EBV DNA per cell. In situ cytohybridization with digoxigenin-lab
onpolyadenylated EBV-encoded RNAs (EBERs) was performed as described
ingle-cell clones monitored for subsequent loss of viral DNA.charted early events in primary EBV infection of humans.
First, our findings suggest that initial EBV contact with
the epithelial cell barrier is marked by viral entry through
the apical cell surface, with release of infectious EBV
basolaterally. Such a pattern of viral entry and release,
effecting transfer of infectious virus across epithelial
boundaries, appears not to be the general rule in polar-
ized epithelium. For example, simian virus 40 and mea-
sles virus use the apical cell membrane for both entry
and release, whereas Semliki Forest virus and vesicular
stomatitis virus transit into and out of cells via the baso-
lateral cell domain (reviewed in Blau and Compans,
1996). Indications that EBV follows a transepithelial route
during acute infection may explain how virus traverses
the mucosal epithelial cell barrier to infect underlying
lymphoid aggregates without physical breakdown of the
epithelial cell sheet.
Since patterned viral entry in polarized cells reflects
asymmetric distribution of viral receptors (Fuller et al.,
984; Clayson and Compans, 1988; Rossen et al., 1994),
vidence for enhanced apical infectivity despite the gen-
ral dispersal of CR2 to all cell surfaces supports the
xistence of an endogenous EBV coreceptor segregated
pically on CR2-transfected MDCK cells. Existence of
uch a coreceptor may explain the disparate outcomes
f IgA-mediated entry by EBV reported in earlier studies
sing this same cell system (Gan et al., 1997). Under
olarized conditions where the polymeric immunoglobu-
in receptor (pIgR) is partitioned basolaterally, EBV/IgA
ted MDCK–pR4CR2 cells. Using the BamHI NJhet fragment of EBV DNA
ght ends indicative of an episomal, latent genome versus linear,
e), BamHI digests of infected cellular DNA were analyzed by Southern
s a Burkitt lymphoma-derived cell line containing two integrated copies
ense (B, top) and antisense (B, bottom) riboprobes for the smallin infec
lar-wei
genom
alwa i
eled sunder Materials and Methods to confirm homogeneity of infection in
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393EBV INFECTION OF POLARIZED EPITHELIUMimmune complexes were transcytosed by pIgR through
MDCK cells without evidence for infection. By contrast, in
nonpolarized cells where cooperation becomes possible
between newly juxtaposed apical and basolateral cell
surface molecules, infection occurred (Gan et al., 1997).
Indications of an EBV coreceptor endogenous to MDCK
cells is part of accumulating evidence from multiple
laboratories for EBV receptors novel to epithelium (Wang
et al., 1998; Yoshiyama et al., 1997; Imai et al., 1998). The
indings in MDCK cells raise the possibility that at least
ome of these receptor molecules are conserved across
pecies.
Finally, the inability of EBV to persist in polarized
DCK cells may reflect the natural progression of acute
BV infection in normal epithelium rather than an artifact
f cell culture. The outcome we observed is unlikely to
epresent mere overgrowth of cultures by cells that have
ost viral DNA, given the faster population doubling time
f the infected cell clones. Loss of EBV from canine-
erived MDCK cells is consistent with earlier reports of
ransient infection produced in human epithelial lines (Li
t al., 1992). Indeed, stable maintenance of latent EBV in
ivo has been postulated to require an undifferentiated
pithelial cell environment (Knox et al., 1996) atypical of
hat encountered by virus during primary infection of
ealthy mucosa. In the normal clinical setting, infection
nd subsequent clearance of residual virus from oropha-
yngeal epithelium could occur well within the 4- to
-week incubation period preceding onset of clinical
nfectious mononucleosis. In what has been described
s a mouse model of infectious mononucleosis induced
y the distantly related gammaherpesvirus MHV-68, in-
ection of epithelial cells resolved weeks prior to the
nset of the mononucleosis-like phase (Doherty et al.,
997). Transience of the epithelial phase of acute infec-
ion may well explain the variable results reported for
pithelial involvement in studies of symptomatic infec-
ious mononucleosis (Lemon et al., 1977; Sixbey et al.,
984; Anagnostopoulos et al., 1995; Karajannis et al.,
997) and is consistent with the prevailing notion that B
ymphocytes constitute the major reservoir for persistent
BV infection in the human host.
MATERIALS AND METHODS
ell lines and virus
Lymphoid cell lines and stock EBV. Controls for ex-
ression of cellular or viral proteins were the pre-B-cell
ine Reh (American Type Culture Collection, Rockville,
D) and Burkitt’s lymphoma-derived line BL2 (Calander
t al., 1987), which are EBV-negative; IB4 (King et al.,
980), Raji (Pulvertaft, 1964), and Namalwa (Henderson
t al., 1983), which maintain EBV in a latent state; and
irus-producing cell lines Akata (Takada et al., 1991) and
95-8 (Miller and Lipman, 1973). Infectious EBV stock
as made from the cell line, Akata, which was induced to
m
Beplicate virus by treatment with anti-human IgG (Takada
nd Ono, 1989). Stock EBV preparations transformed 50%
f primary lymphocyte cultures at a dilution of 1024 in the
lymphocyte transformation assay (Moss and Pope, 1972).
Recombinant Akata virus bearing the neomycin-resistant
cassette (gift of L. Hutt-Fletcher, University of Missouri at
Kansas City; Borza and Hutt-Fletcher, 1998) was pro-
duced as above for use in a single experiment.
Epithelial line MDCK–pR4CR2. cDNA encoding the in-
tact CR2 open reading frame (Li et al., 1992; gift of M.
irkenbach, University of Chicago) was inserted by blunt
igation into pREP4 (Invitrogen, Carlsbad, CA), an episo-
al mammalian expression vector containing the EBV
rigin of plasmid replication, the EBNA-1 coding region
o allow high-copy replication, the RSV LTR promoter,
nd a hygromycin-selection marker. Constructs pREP4-
R2 or pREP4 alone were transfected into MDCK cells,
train II (low resistance, 100 to 300 V/cm2) (gift of R.
Owens, St. Jude Children’s Research Hospital) using
Lipofectamine (Gibco BRL, Life Technologies Inc., Gaith-
ersburg, MD) as per the manufacturer’s instructions.
Transfected cells were selected on hygromycin B (Cal-
biochem–Novabiochem Corp., La Jolla, CA) and, after 4
weeks in culture, single-cell clones were established.
Cell clones expressing high levels of CR2 were selected
for further experimentation. CR2 expression in MDCK–
pR4CR2 cells, relative to lymphoid cells, was shown by
metabolically labeling cultures with [35S]methionine (200
mCi/ml, ICN, Costa Mesa, CA). Cells were lysed with
detergent, and protein lysates were quantified (Bio-Rad
Protein Assay, Bio-Rad, Richmond, CA) and then immu-
noprecipitated with purified anti-CR2 antibody HB-5 (Ted-
der et al., 1984). Radiolabeled proteins were separated
on denaturing 10% polyacrylamide gels containing so-
dium dodecyl sulfate (SDS), and the proteins were de-
tected by autoradiography of the dried slab gels.
Polarized epithelial growth and receptor expression
MDCK–pR4CR2 cells were cultured on permeable
membranes (pore size, 0.45 mm) in microwell chambers
(Transwells; Costar, Cambridge, MA) in minimum essen-
tial medium with 10% bovine serum. After 96 h in culture,
the integrity of each monolayer was ascertained by mea-
suring transmembrane electrical resistance (TER) with a
Millicell-ERS meter (Millipore Corp., Bedford, MA). MDCK
epithelial cultures selected for experiments were re-
quired to have a TER of greater than 100 V/cm2, a
easurement equated with monolayer impermeability to
he macromolecule inulin and the polarized expression
f cellular proteins (Gan et al., 1997).
To localize CR2 expression to particular cell surface
omains, MAb HB-5 was applied selectively either to the
pical surface of cells or to their basolateral membranes
ade accessible by growth on porous cell supports.
ound antibody was detected by standard indirect im-
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394 CHODOSH ET AL.munofluorescence staining with fluorescein isothiocya-
nate-conjugated (FITC) goat anti-mouse immunoglobulin
(Ig) G (Southern Biotechnologies, Birmingham, AL). Alter-
natively, bound HB-5 was quantified by application of
rabbit anti-mouse IgG (Southern Biotechnology) followed
by 1 3 105 cpm 125I-labeled protein A (1.85 MBq 50 mCi,
mersham Life Sciences, Buckinghamshire, UK). Filters
ere washed three times with phosphate-buffered saline
nd the amount of radioactivity was determined in a
eckman scintillation counter (Beckman, Irvine, CA). Lev-
ls of nonspecific binding of 125I-labeled protein A were
etermined using MDCK–pR4 cells processed as above,
nd these background counts were subtracted from ex-
erimental readings obtained with MDCK–pR4CR2. Val-
es in each experiment represent the mean from tripli-
ate filters. A third approach utilized dual immunofluo-
escence on live cells grown to confluence on glass
overslips, incubated at 4°C with the primary MAb HB-5,
nd then incubated with Texas red-conjugated goat anti-
ouse IgG (Southern Biotechnology). Stained intact and
GTA (Sigma, St. Louis, MO)-disrupted monolayers
Owens and Compans, 1989) were fixed in 3% parafor-
aldehyde and reincubated with HB-5. After being
ashed, EGTA- and mock-treated cells were incubated
ith FITC-labeled goat anti-mouse IgG. Simultaneous
ual fluorescence was visualized using an Olympus
H-2 microscope equipped with an Omega triple-dye
ilter set (Olympus Corp., Lake Success, NY).
irus binding and MDCK cell infection
3H-labeled EBV (gift of L. Hutt-Fletcher, University of
issouri at Kansas City) was prepared from Akata cells
s previously described (Takada and Ono, 1989; Sixbey
t al., 1987). Trichloracetic acid precipitation of labeled
tock virus yielded 7173 cpm incorporated out of a total
f 23,135 cpm for the same volume of unprecipitated
irus stock. For viral binding studies, confluent monolay-
rs of MDCK–pR4CR2 or MDCK–pR4 cells were rinsed in
ce-cold phosphate-buffered saline. 3H-labeled EBV was
dsorbed to the apical or basolateral surface of culture
embranes in the presence of 100 mg unlabeled thymi-
dine and then overlaid with cold medium at 4°C for 3 h
to maximize binding. CR2-positive (Raji) and -negative
(Reh) lymphocyte cultures were similarly processed but
as cell pellets. Cells were thoroughly rinsed with cold
PBS to remove excess virus, and bound virus was quan-
tified by total counts retained. For infection studies, un-
labeled virus was bound as above and warm medium
was subsequently added to both sides of the filter for
incubation at 37°C.
Immunofluorescence and immunoblotting
for viral antigensCells were fixed in acetone and examined for EBV
protein expression by standard indirect immunofluores-cence techniques described above. MAb BZ.1, specific
for the immediate-early protein BZLF1 (gift of L. S. Young,
University of Birmingham, UK; Young et al., 1991), was
used as primary antibody. For immunolocalization of EBV
protein in polarized epithelium, MDCK–pR4CR2 cells in-
fected apically were fixed 72–96 h postinfection with 4%
paraformaldehyde for 30 min and then permeabilized
with 1% Triton 100 for 5 min. Anti-gp350/220 MAb 2L10
(Tanner et al., 1987) was added to both membrane sur-
faces for a 1-h incubation, washed with phosphate-buff-
ered saline, and then stained with FITC-labeled goat
anti-mouse IgG. For double-staining, MAb BZ.1 was first
applied followed by Texas red-conjugated goat anti-
mouse IgG. Confocal imaging was performed on a Bio-
Rad MRC 10W4 Laser Sharp system (Bio-Rad, Hercules,
CA) equipped with an Olympus Bx50 microscope with a
60X objective. Optical sections at a thickness of 0.7 mm
were collected through the samples, stored in memory,
and used individually or after 3-dimensional reconstruc-
tion.
For immunoblotting, cells were lysed in SDS–PAGE
sample buffer containing 10% b-mercaptoethanol. Sam-
ples were sonicated, electrophoresed on 7.5% SDS–poly-
acrylamide gels, and transferred to polyvinylidene fluo-
ride membranes (Millipore, Bedford MA) using a semidry
electroblotter (Bio-Rad, Richmond, CA). To detect BZLF1,
blots were incubated with BZ.1 at a 1:1000 dilution and
antibody binding was detected by chemiluminescence
per the manufacturer’s protocol (Rad-Free kit; Schleicher
& Schuell, Keene, NH).
EBV nucleic acid hybridization and PCR analyses
The molecular configuration of EBV termini (linear or
episomal) was determined using a 32P-labeled BamHI
NJhet fragment of EBV DNA that spans the terminal
repeats (Raab-Traub and Flynn, 1986). Total cellular
DNA from infected MDCK–pR4CR2 cells was digested
with BamHI restriction endonuclease, loaded at 10 mg
f DNA per well, separated by electrophoresis in a
.8% agarose gel, and then transferred to nylon mem-
ranes for hybridization. EBV status of single-cell
lones of infected MDCK–pR4CR2 cells was deter-
ined by in situ cytohybridization using digoxigenin-
labeled riboprobes specific for EBER1 (MacMahon et
al., 1991). Bound probe was detected by an anti-digoxi-
genin antibody–alkaline phosphatase conjugate
(Boehringer Mannheim, Mannheim, Germany) as per
the manufacturer’s protocol. PCR primer sequences
and RT-PCR analysis for EBNA1 and LMP2 were as
described elsewhere (Brooks et al., 1992). PCR prim-
ers for CR2 DNA were 59-ATTGCTGGACAGGGAGT-
TGC-39 and 59-CACAGACTGGTGCAGATGGC-39 (59
base coordinates 841 and 1268, respectively; Fujisaku
et al., 1989). PCR amplification was performed as pre-
viously described (Gan et al., 1997).
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